Chemoembolization for liver metastases from medullary thyroid carcinoma

Détails

ID Serval
serval:BIB_963F663C4CDC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Chemoembolization for liver metastases from medullary thyroid carcinoma
Périodique
J Clin Endocrinol Metab
Auteur(s)
Fromigue J., De Baere T., Baudin E., Dromain C., Leboulleux S., Schlumberger M.
ISSN-L
0021-972X (Print)0021-972X (Linking)
Statut éditorial
Publié
Date de publication
2006
Peer-reviewed
Oui
Volume
91
Numéro
7
Pages
2496-9
Langue
anglais
Notes
Fromigue, JDe Baere, TBaudin, EDromain, CLeboulleux, SSchlumberger, MengCase ReportsReview2006/04/13 09:00J Clin Endocrinol Metab. 2006 Jul;91(7):2496-9. Epub 2006 Apr 11.
Résumé
BACKGROUND: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor. Distant metastases are the main cause of cancer-related death. Systemic chemotherapy produces only rare tumor responses. Somatostatin analogs and other available modalities are poorly effective to control symptoms. AIMS: The aim of our study was to evaluate the impact of liver transarterial chemoembolization (TACE) in MTC patients with predominant and progressive liver metastases. PATIENTS AND METHODS: Twelve MTC patients underwent 18 TACE courses (mean, 1.5; range, 1-2). Response evaluation criteria in solid tumors were used to evaluate tumor responses. Symptomatic responses were defined by more than a 25% decrease of symptoms intensity. RESULTS: Partial radiological tumor response was obtained in five patients (42%) with a median duration of 17 months (mean, 19; range, 15-28 months), stabilization in five (42%) with a median duration of 24 months (mean, 24; range, 4-39 months), and progression in the remaining two (16%). The five partial tumor responses were observed in the nine patients with less than 30% liver involvement. Clinical response was observed in two of the five patients with diarrhea. Carcinoembryonic antigen did not appear to be a useful marker in this setting. Significant grade 3-4 toxicity was observed in one patient who had a major tumor necrosis after TACE. CONCLUSION: TACE should be considered for treating MTC patients with progressive and predominant liver metastasis, and preferably at an early stage during the course of metastatic disease.
Mots-clé
Adult, Aged, Aged, 80 and over, Calcitonin/blood, Carcinoembryonic Antigen/blood, Carcinoma, Medullary/*secondary, *Chemoembolization, Therapeutic/adverse effects/methods, Female, Humans, Liver/blood supply, Liver Neoplasms/radiography/*secondary/*therapy, Male, Middle Aged, *Thyroid Neoplasms, Tomography, X-Ray Computed, Treatment Outcome
Open Access
Oui
Création de la notice
16/09/2016 10:14
Dernière modification de la notice
20/08/2019 14:58
Données d'usage